Related Experiment Video

Updated: Apr 23, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

6.5K

Posttranslational modifications of RUNX1 as potential anticancer targets

S Goyama1, G Huang1, M Kurokawa2

  • 1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Oncogene
|September 30, 2014
PubMed

Insights

RUNX1 is crucial in blood cell formation and cancer. Targeting its post-translational modifications (PTMs) offers a promising strategy for developing novel anticancer therapies.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • RUNX1 is a key transcription factor regulating hematopoiesis.
  • RUNX1's dysregulation is linked to hematopoietic neoplasms and solid tumors, acting as both a promoter and suppressor.
  • RUNX1's role in cancer makes it a significant therapeutic target.

Purpose of the Study:

  • To review the context- and dosage-dependent roles of RUNX1 in various neoplasms.
  • To provide a comprehensive overview of RUNX1 post-translational modifications (PTMs).
  • To discuss the contribution of aberrant RUNX1 PTMs to tumorigenesis and explore therapeutic strategies targeting these modifications.

Main Methods:

  • Literature review of existing studies on RUNX1 in cancer.
  • Analysis of biochemical and biological data on RUNX1 PTMs.
  • Discussion of therapeutic implications of targeting RUNX1 PTMs.

Main Results:

  • RUNX1 PTMs, including phosphorylation, acetylation, methylation, and ubiquitination, critically regulate its activity.
  • These PTMs influence RUNX1-mediated transcription, protein degradation, and interactions, impacting cancer development.
  • Aberrant PTMs of RUNX1 are implicated in tumorigenesis.

Conclusions:

  • Targeting RUNX1 PTMs presents a viable strategy for developing novel anticancer therapies.
  • Understanding RUNX1's multifaceted roles and PTMs is essential for effective cancer treatment.
  • Further research into RUNX1 PTMs can unlock new therapeutic avenues for various cancers.

More Related Videos

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins08:12

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins

Published on: January 8, 2018

13.5K
Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN11:42

Genome-wide Mapping of Histone Modifications and Transcription Factor Binding Sites in Neuroendocrine Small Cell Lung Cancer Cell Lines Using CUT&RUN

Published on: April 3, 2026

81

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.3K